The worldwide molecular spectrum and distribution of thalassaemia: a systematic review


Ebrahimi M., Mohammadi-Asl J., RAHIM F.

ANNALS OF HUMAN BIOLOGY, vol.48, no.4, pp.307-312, 2021 (SCI-Expanded, SSCI, Scopus) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 48 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.1080/03014460.2021.1909135
  • Journal Name: ANNALS OF HUMAN BIOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, Academic Search Premier, International Bibliography of Social Sciences, Anthropological Literature, BIOSIS, CAB Abstracts, EMBASE, Geobase, MEDLINE, SportDiscus, Veterinary Science Database
  • Page Numbers: pp.307-312
  • Kocaeli University Affiliated: No

Abstract

Context Thalassaemia is one of the most common inherited autosomal recessive disorders around the world. A considerable amount of literature has been published about the type of mutations and the prevalence of thalassaemia, but findings are often contradictory. Objective This systematic review aimed to provide a comprehensive view of the prevalence of thalassaemia-associated mutations in different countries, their effect on haemoglobin (Hb) levels, as well as reporting thalassaemia-associated rare mutations. Methods A systematic search of the literature was carried out through major indexing databases (MEDLINE/PubMed, Scopus, EMBASE, Cochrane central, and ISI web of science) using keywords: "Co-inheritance, alpha alpha, beta, thalassaemia" and "alpha-beta thalassaemia, Mediterranean anemia, mutations" from 1998-September 2019. Hand-searching was also performed. There was no language restriction. Results The initial searches yielded 1059 studies, of which 92 articles were included following inclusion and exclusion criteria. Of these, 3.3% (3) of articles were cohort studies, and 96.7% (89) of the remaining articles were cross-sectional studies. Our findings showed that 45.6% (42) of researchers investigated beta-thalassaemia, 22.9% (21) alpha alpha-beta thalassaemia, and 31.5% (29) alpha thalassaemia. Conclusion The present study provides valuable information about the spectrum of thalassaemia-associated mutations, which can be useful for preventing thalassaemia, reducing costs of care, reducing the treatment-related side effects, and showing the most defective mutations.